Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.55 |
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.51 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.48 |
| ▸ | WIZ | O95785 | 1/20 | 0.48 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27207467 | 1.00 | CRBN (0.55) | CRBNESR1CSNK1A1IKZF2IKZF1 | |
| SCHEMBL30822469 | 1.00 | CRBN (0.55) | CRBNESR1CSNK1A1IKZF2IKZF1 | |
| SCHEMBL29841437 | 0.99 | CRBN (0.54) | CRBNESR1CSNK1A1IKZF2IKZF1 | |
| SCHEMBL27207449 | 0.99 | CRBN (0.54) | CRBNESR1CSNK1A1IKZF2IKZF1 | |
| SCHEMBL24735220 | 0.99 | CRBN (0.54) | CRBNESR1CSNK1A1IKZF2IKZF1 | |
| SCHEMBL30822406 | 0.99 | CRBN (0.54) | CRBNESR1CSNK1A1IKZF2IKZF1 | |
| SCHEMBL24734973 | 0.97 | CRBN (0.56) | CRBNESR1CSNK1A1IKZF2IKZF1 | |
| SCHEMBL31586767 | 0.97 | CRBN (0.56) | CRBNESR1CSNK1A1IKZF2IKZF1 | |
| SCHEMBL31586284 | 0.94 | CRBN (0.58) | CRBNESR1CSNK1A1IKZF2IKZF1 | |
| SCHEMBL30889709 | 0.93 | CRBN (0.55) | CRBNESR1CSNK1A1GSPT1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4501327-A2 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON S TYROSINEKINASE (BTK) DEGRADERS | Accutar Biotechnology Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4039688-B1 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS | ACCUTAR BIOTECHNOLOGY INC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240132502-A1 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
| US-11530222-B2 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2022169798-A2 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| EP-4039688-A2 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS | Accutar Biotechnology Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530222-B2 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders | BTK, LYN, SYK | CRBN 692/4885ESR1 3739/4885CSNK1A1 160/4885 |
| US-20240132502-A1 | SUBSTITUTED PYRROLOPYRIMIDINE AND PYRAZOLOPYRIMIDINE AS BRUTON'S TYROSINE KINASE (BTK) DEGRADERS | BTK, LYN, SYK | CRBN 439/4885ESR1 3270/4885CSNK1A1 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.